Riverhead Capital Management’s Emergent Biosolutions EBS Stock Holding History

Riverhead Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$336K	Buy	6,436 +500	+8%	+$23.3K	0.01%	902
2019 Q2	$287K	Buy	5,936 +100	+2%	+$4.79K	0.01%	979
2019 Q1	$295K	Hold	5,836	–	–	0.01%	950
2018 Q4	$346K	Hold	5,836	–	–	0.02%	817
2018 Q3	$384K	Hold	5,836	–	–	0.01%	893
2018 Q2	$295K	Hold	5,836	–	–	0.01%	900
2018 Q1	$307K	Buy	5,836 +700	+14%	+$34.9K	0.01%	865
2017 Q4	$239K	Buy	5,136 +900	+21%	+$37.9K	0.01%	986
2017 Q3	$171K	Buy	4,236 +1,194	+39%	+$43.2K	0.01%	1053
2017 Q2	$103K	Buy	3,042 +1,542	+103%	+$47.6K	0.01%	1208
2017 Q1	$44K	Sell	1,500 -1,400	-48%	-$42.6K	﹤0.01%	1297
2016 Q4	$95K	Hold	2,900	–	–	0.01%	986
2016 Q3	$91K	Sell	2,900 -400	-12%	-$11.6K	0.01%	945
2016 Q2	$140K	Sell	3,300 -4,540	-58%	-$178K	﹤0.01%	1041
2016 Q1	$285K	Sell	7,840 -160	-2%	-$5.65K	﹤0.01%	1139
2015 Q4	$320K	Buy	+8,000	New	+$279K	﹤0.01%	1115

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Riverhead Capital Management's EBS Position: Q3 2019 in Review

Riverhead Capital Management increased its Emergent Biosolutions (EBS) stake by 8.4% in Q3 2019, buying an estimated $23.3K and bringing the position to 6,436 shares worth $336K. The position accounts for 0.01% of the portfolio, ranked #902.

Riverhead Capital Management first reported a position in EBS in Q4 2015 and has held it in 16 quarters since. The position peaked at $384K in Q3 2018. 244 funds tracked by Wall St. Rank hold EBS as of Q3 2019.

Riverhead Capital Management held 6,436 shares of Emergent Biosolutions worth $336K as of Q3 2019.
Riverhead Capital Management bought 500 Emergent Biosolutions shares in Q3 2019, an estimated $23.3K.
Emergent Biosolutions made up 0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #902 holding.
Riverhead Capital Management first reported a position in Emergent Biosolutions in Q4 2015 and has held it in 16 quarters since.
Riverhead Capital Management's Emergent Biosolutions position peaked at $384K in Q3 2018.
244 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.